Drug Profile

Research programme: oral insulin - Aphios Corporation

Alternative Names: APH-0907; oral insulin - Aphios

Latest Information Update: 25 Nov 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Aphios Corporation
Class Insulins; Pancreatic hormones
Mechanism of Action Ornithine decarboxylase stimulants; Pancreatic hormone receptor agonists; Phosphokinase stimulants; Protein tyrosine kinase stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

25 Nov 2021 Preclinical trials in Diabetes mellitus in USA (PO) prior to November 2021 (Aphios Corporation pipeline, November 2021)
20 Oct 2014 Research programme: oral insulin - Aphios Corporation is available for licensing as of 20 Oct 2014. http://www.aphios.com/products/therapeutic-product-pipeline/diabetes/aph-0907.html
17 Dec 2012 Early research in Diabetes mellitus in USA (PO)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com